By Reza Ganjavi
BluShield’s homepage currently declares: “Clinically proven. Independently reviewed. PubMed indexed.”
One direct question exposed the weakness at the center of BluShield’s sales pitch: Where is the clinical proof?
The response produced farm anecdotes about cows and chickens, customer before-and-after stories, and a company-funded pilot involving 25 adults. The pilot used one treatment arm. Every participant received the device. The protocol omitted a sham group, an untreated group, random assignment and blinding.
The 25-person pilot is the human evidence BluShield cites while making that categorical claim.
BluShield’s representative described its older testing as “grassroots style” and “real world.” The email recited dramatic farm observations involving cows and chickens, followed by references to customers and doctors comparing biological measurements before and after device use.
These stories establish nothing about causation. Farm conditions change. Feed changes. Disease patterns change. Housing, weather, management, measurement practices and countless other variables change. Customer expectations and behavior also change. An uncontrolled before-and-after story cannot isolate BluShield as the cause of anything.
Calling anecdotes “real world” gives weak evidence a friendly label. The scientific defect remains intact.
BluShield then relied on a 12-week, single-arm pilot involving 25 adults. Researchers measured participants before and after they began using the device. The study lacked the basic comparison structure required to determine whether the device caused any reported change.
· One treatment arm
· Twenty-five participants
· Every participant received the device
· No sham-device comparison
· No untreated comparison group
· No random assignment
· No participant blinding
The design left expectation effects, behavior changes, ordinary biological fluctuation, regression toward the mean and other confounding factors unresolved. Measuring many biomarkers with sophisticated laboratory tools does not solve that structural failure.
The paper itself concedes the point:
“Controlled studies are needed to mitigate potential sources of confounding in this single-arm pilot study.”
That sentence should have ended any claim of established efficacy. The authors identified potential confounding in the single-arm pilot and called for controlled studies. BluShield converted the preliminary findings into sales language communicating proof.
Once the study design was challenged, the representative admitted that BluShield had originally intended to conduct a “double blind, placebo controlled study.” Cost was described as prohibitive. The company therefore “simplified it as much as we could.”
This is the central admission. BluShield understood the value of blinding and placebo control. It planned a design capable of producing stronger evidence. Budget considerations led to a simplified study that left causation unresolved. The resulting pilot was then used to support a categorical claim of clinical proof.
A company may choose the research it can afford. That choice fixes the limit of what the resulting evidence can honestly support.
BluShield later emphasized that its completed study cost more than $100,000 and claimed that the preferred design, including a Faraday-shielded setting, would have exceeded $1 million.
This cost argument evades the basic defect. The central problem was the absence of a credible comparison group and blinding. A $100,000 one-arm pilot remains a one-arm pilot. Expensive laboratory panels do not manufacture causation. A Faraday chamber does not excuse the omission of basic controls.
Study cost is a business fact. It adds zero scientific weight to the result.
When confronted with the missing controls, BluShield repeatedly pointed to Institutional Review Board oversight, peer review, PubMed indexing and technical statistical material. These labels sound impressive to consumers. They do not answer the causal question.
Institutional Review Board oversight concerns the protection of the rights and welfare of human participants. It does not certify that a commercial product works.
Peer review means that a journal accepted a pilot paper for publication. Journals publish preliminary and feasibility studies. Publication cannot create randomization, blinding or a comparison group after the study has ended.
PubMed indexing means the article appears in a biomedical literature database. The U.S. National Library of Medicine expressly states that database inclusion does not imply endorsement by NLM, NIH or the federal government. Indexing provides no finding that the device is effective.
In this sales context, these credentials function as props surrounding a study whose central methodological weakness remains untouched.
The representative eventually asked whether the Q-Q plot associated with the methylation analysis had been reviewed. That response illustrates the entire problem: technical complexity was offered where basic experimental control was missing.
A Q-Q plot compares quantiles to assess whether data follow or share a distribution. It cannot determine whether BluShield caused a change when every participant received the device and no equivalent comparison group was observed. Statistical decoration cannot rescue a study design that never isolated the product’s effect.
The exchange followed a clear pattern:
· A request for proof produced anecdotes and an uncontrolled pilot.
· A methodological critique produced references to peer review, IRB oversight and PubMed.
· A challenge concerning blinding and controls produced a budget explanation.
· A challenge to the study design produced a reference to a Q-Q plot.
Each response moved further away from the decisive question: What credible controlled evidence shows that the device caused the claimed protective effect in humans? In the exchange, BluShield cited no randomized, blinded, sham-controlled human trial.
The documented record supports a blunt conclusion. BluShield funded a small, uncontrolled pilot, acknowledged simplifying the planned design, and promoted the resulting associations with a level of certainty the study did not earn.
In my assessment, this is science-washing: preliminary company-funded findings wrapped in technical vocabulary, institutional labels and impressive-looking statistics to create an appearance of clinical proof.
The available evidence has not demonstrated that BluShield protects humans from EMF-related harm. It has demonstrated that 25 participants used a device during an uncontrolled before-and-after study whose authors called for controlled research.
Consumers considering these EMF gadgets deserve that unvarnished description. They deserve to know that the company’s own representative admitted that a double-blind, placebo-controlled design was dropped over cost and replaced with a study “simplified” as far as the company could manage.
A sales claim does not become science through repetition. A weak pilot does not become proof through PubMed indexing. A Q-Q plot does not become a control group. BluShield’s evidence collapses under the most basic scientific scrutiny.
This article critiques BluShield’s scientific and marketing claims using the company’s written correspondence, its published pilot study, its trial-registration record and its public website. “Science-washing” expresses the author’s assessment of the documented mismatch between the strength of the evidence and the certainty of the advertising. The article alleges no criminal conduct and makes no claim concerning any individual’s private intent. BluShield may identify any material factual error or provide controlled, independently replicated human evidence for review.
BluShield USA correspondence, 16–17 March 2026.
D’Adamo et al., “A Pilot Study Evaluating the Feasibility and Efficacy of an In-Home Resonance-Based Electromagnetic Field Protection Device on Improving Markers of Health and Cognitive Function Among a Sample of Healthy Adults,” PMID 39355415.
https://pubmed.ncbi.nlm.nih.gov/39355415/
ClinicalTrials.gov, NCT05001646, “Electromagnetic Field Protection Device Use Impact in Healthy Volunteers.”
https://clinicaltrials.gov/study/NCT05001646
BluShield USA public website, accessed 19 July 2026.
https://www.blushield.com/
U.S. National Library of Medicine, PubMed Disclaimer.
https://pubmed.ncbi.nlm.nih.gov/disclaimer/
U.S. Department of Health and Human Services, Office for Human Research Protections, IRB and human-subject protections.
https://www.hhs.gov/ohrp/index.html
U.S. National Institute of Standards and Technology, “Quantile-Quantile Plot.”
https://www.itl.nist.gov/div898/handbook/eda/section3/eda33o.htm